Clinical Trial

Selection and Efficacy-Influencing Factors of First-Line Biologic Agents in Moderate-to-Severe Ulcerative Colitis

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 3, 2025 (before its estimated November 20, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this prospective, multicenter, real-world study is to compare the efficacy differences and influencing factors of different first-line biologics in patients with moderate to severe ulcerative colitis. The question that this study aims to answer is: When treating patients with moderate to severe ulcerative colitis, should IFX or VDZ be prioritized as the first-line choice for biologics?, Which biological agent has better therapeutic effect?. Researchers will observe and follow up with patients with moderate to severe ulcerative colitis treated with different biologics on the front line, evaluate their condition changes, eliminate relevant interfering factors, and draw the final conclusion.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-29.
Status change: Not Yet Recruiting → Recruiting 2025-07-01
Trial Details
NCT Number NCT06962020
Lead Sponsor Xijing Hospital of Digestive Diseases
Conditions Ulcerative Colitis (UC)
Enrollment 400 participants
Start Date 2025-04-30
Primary Completion 2025-11-20 (estimated)
Study Completion 2025-11-20 (estimated)
Updated on ClinicalTrials.gov 2025-07-03